- 英文名称Glycyrrhetinate
- 中文名称18α-甘草次酸
- IUPAC名称(2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bS)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid
- 其它别名(3beta,18alpha,20beta)-3-Hydroxy-11-oxoolean-12-en-29-oic acid
- CAS编号1449-05-4
- MFCD编号:MFCD00064897
- EINECS号:215-907-9
- FDA UNII编号:X6NYL2CP2E
- 分子式:C30H46O4分子量:470.68
- 产品CID: 684618
- 产品分类生物化工 → 提取物
- 相似结构搜索
- 产品信息参考
;
;
;
;
- InChIKey: MPDGHEJMBKOTSU-XPWZLSEINA-N
- InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/
- 计算化学: 氢键受体数4.0氢键供体数2.0可旋转键数1.0
欧盟法规
ECHA物质C&L通报REACH预注册上下游产品
enoxolone methyl 3-benzoyl-18α-glycyrrhetinate glycyrrhetic acid 3-O-mono-β-D-glucuronide 3-oxo-18β-glycyrrhetinic acid Glycyrrhetinsaeure-β-D-glucopyranosylester Glycyrrhetinsaeure-methylester (3β,18α,20β)-3-hydroxy-11-oxoolean-12-en-29-oic acid diphenylmethyl ester 📜甘草次酸置于氢氧化钾体系中,用 二乙二醇 用作溶剂,化学反应 2.0H,以45%的收率获得18α-甘草次酸
参考文献:甘草次酸衍生物的乳糖苷的合成及溶血性能
标题:甘草次酸衍生物的乳糖苷的合成及溶血性能
摘要:描述了甘草次酸,其11-脱氧和18α-衍生物及其甲基酯的乳糖苷的部分合成.糖苷配基结构对标题化合物溶血特性的影响进行了讨论,并与齐墩果酸衍生物进行了比较.此外,我们描述了18α-甘草次酸的优化制备方法.
Doi:10.1007/s706-002-8243-6
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2912110000-甲醛 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2019029993-A1
优先权日:2017-07-26
标 题 :Quality of life extension therapies relating to aging, food allergies, pain and reduced vigor by managing molecular, cellular and subcellular biochemical requirements of mitochondria and other organelle processes
发明人:POSTREL RICHARD
权利人:POSTREL RICHARD
摘要:This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as an animal continues to age, rebalancing the organism's metabolism through providing mitochondrial supplements, and serially revisiting effects of the early stages of treatment to redirect or improve activity of all aspects of life and metabolism.
专利号:US-2019030044-A1
优先权日:2017-07-26
标 题:Human life extension therapy through molecular, cellular and subcellular management of biochemical requirements of mitochondria and of other organelle processes associated with the advent of disease and/or aging
发明人:POSTREL RICHARD
权利人:POSTREL RICHARD
摘要:This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as a human continues to age, rebalancing the organism's metabolism through providing mitochondrial supplements, and serially revisiting effects of the early stages of treatment to redirect or improve activity of all aspects of life and metabolism.
专利号:US-9575067-B2
优先权日:2007-05-23
标 题 :Polymeric carriers for immunohistochemistry and in situ hybridization
发明人:KOSMEDER II JERRY W; KERNAG CASEY A; JOHNSON DONALD; BIENIARZ CHRISTOPHER
权利人:VENTANA MED SYST INC
摘要:Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
专利号:US-2020078333-A1
优先权日:2016-12-21
标 题 :Healthier Aging in Domesticated Animals
发明人:POSTREL RICHARD
权利人:POSTREL RICHARD
摘要:This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as an animal continues to age, rebalancing the organism's m
专利号:CN-115490746-B
优先权日:2021-06-17
标题:A microwave-assisted synthesis method of 18α-glycyrrhetinic acid and its derivatives
专利号:CN-115490746-A
优先权日:2021-06-17
标题 :Microwave-assisted synthesis method of 18 alpha-glycyrrhetinic acid and derivatives thereof